Sosei Group Corp. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,215
5,573
10,068
13,899
28,281
Total Accounts Receivable
100
3,060
97
1,382
1,810
Other Current Assets
150
386
470
538
825
Total Current Assets
7,464
9,019
10,635
15,821
30,916
Net Property, Plant & Equipment
60
266
270
422
1,156
Total Investments and Advances
-
-
-
605
6,043
Intangible Assets
6,148
38,140
34,739
31,124
31,355
Other Assets
41
44
52
108
10
Total Assets
14,582
47,833
47,354
48,087
69,486
ST Debt & Current Portion LT Debt
-
19,877
1,990
1,990
2,995
Accounts Payable
43
202
-
-
-
Income Tax Payable
25
34
70
1,991
39
Other Current Liabilities
139
1,355
1,398
1,630
2,561
Total Current Liabilities
207
21,468
3,458
5,611
5,595
Long-Term Debt
-
-
6,847
4,910
6,178
Deferred Taxes
869
4,091
2,030
3,171
3,071
Other Liabilities
7
7,068
10,092
6,030
5,750
Total Liabilities
214
32,991
24,085
19,726
20,600
Common Equity (Total)
14,355
14,601
23,143
28,355
48,882
Total Shareholders' Equity
14,355
14,601
23,143
28,355
48,882
Total Equity
14,355
14,842
23,269
28,359
48,886
Liabilities & Shareholders' Equity
14,582
47,833
47,354
48,085
69,486
Accumulated Minority Interest
-
241
126
4
4
Non-Equity Reserves
13
-
-
-
-

About Sosei Group

View Profile
Address
PMO Hanzomon, 11/F
Tokyo Tokyo 102
Japan
Employees -
Website http://www.sosei.com
Updated 07/08/2019
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). Its proprietary StaR (Stabilised Receptor) technology and structure-based drug design (SBDD) platform enables development of drugs for highly validated, yet historically undruggable or challenging GPCRs. The company has multiple programs targeting Alzheimer's disease, schizophrenia, immuno-oncology, migraine, metabolic disease and other rare and specialty indications.